{
    "root": "644b9559-ef06-45ca-b3b5-c58587463608",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "LYBALVI",
    "value": "20250228",
    "ingredients": [
        {
            "name": "olanzapine",
            "code": "N7U69T4SZR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7735"
        },
        {
            "name": "samidorphan L-malate",
            "code": "0AJQ5N56E0",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_177605"
        },
        {
            "name": "lactose monohydrate",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "microcrystalline cellulose",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "crospovidone",
            "code": "2S7830E561"
        },
        {
            "name": "magnesium stearate",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "silicon dioxide",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "hypromellose, unspecified",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "titanium dioxide",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "triacetin",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        },
        {
            "name": "ferric oxide yellow",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "ferric oxide red",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FD&C blue no. 2--aluminum lake",
            "code": "4AQJ3LG584"
        }
    ],
    "indications": {
        "text": "lybalvi indicated treatment : schizophrenia adults bipolar disorder adults acute treatment manic mixed episodes monotherapy adjunct lithium valproate maintenance monotherapy treatment",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "indication recommended starting dose ( olanzapine/samidorphan ) recommended dose ( olanzapine/samidorphan ) schizophrenia ( 2.2 ) 5 mg/10 mg 10 mg/10 mg 10 mg/10 mg 15 mg/10 mg 20 mg/10 mg bipolar disorder ( manic mixed episodes ) ( 2.3 ) 10 mg/10 mg 15 mg/10 mg 5 mg/10 mg 10 mg/10 mg 15 mg/10 mg 20 mg/10 mg bipolar disorder adjunct lithium valproate ( 2.3 ) 10 mg/10 mg 10 mg/10 mg 15 mg/10 mg 20 mg/10 mg full prescribing information recommended titration maximum recommended . ( 2.2 , 2.3 ) administer lybalvi daily without food . divide tablets combine strengths . ( 2.4 ) recommended starting 5 mg/10 mg daily patients predisposition hypotensive , potential slower metabolism olanzapine , may pharmacodynamically sensitive olanzapine . ( 2.5 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "lybalvi contraindicated patients : using opioids [ ( 5.3 , 5.4 ) , ( 7.3 ) ] . undergoing acute opioid withdrawal [ ( 5.3 , 5.4 ) , ( 7.3 ) ] . lybalvi administered lithium valproate , refer lithium valproate prescribing information products [ ( 5.18 ) ] .",
    "indications_original": "LYBALVI is indicated for the treatment of:\n\n                  \n                     Schizophrenia in adults\n\n                     Bipolar I disorder in adults\n                           Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate\n\n                           Maintenance monotherapy treatment",
    "contraindications_original": "Indication Recommended Starting Dose (olanzapine/samidorphan) Recommended Dose (olanzapine/samidorphan) Schizophrenia ( 2.2 ) 5\u00a0mg/10\u00a0mg or 10\u00a0mg/10\u00a0mg 10\u00a0mg/10\u00a0mg 15\u00a0mg/10\u00a0mg 20\u00a0mg/10\u00a0mg Bipolar I disorder (manic or mixed episodes) ( 2.3 ) 10\u00a0mg/10\u00a0mg or 15\u00a0mg/10\u00a0mg 5 mg/10 mg 10\u00a0mg/10\u00a0mg 15\u00a0mg/10\u00a0mg 20\u00a0mg/10\u00a0mg Bipolar I disorder adjunct to lithium or valproate ( 2.3 ) 10\u00a0mg/10\u00a0mg 10\u00a0mg/10\u00a0mg 15\u00a0mg/10\u00a0mg 20\u00a0mg/10\u00a0mg See the full prescribing information for the recommended titration and maximum recommended dosage. ( 2.2 , 2.3 ) Administer LYBALVI once daily with or without food. Do not divide tablets or combine strengths. ( 2.4 ) Recommended starting dosage is 5 mg/10 mg once daily in patients who have a predisposition to hypotensive reactions, have potential for slower metabolism of olanzapine, or may be more pharmacodynamically sensitive to olanzapine. ( 2.5 )",
    "adverseReactions_original": "LYBALVI is contraindicated in patients:\n\n                  \n                     who are using opioids [see Warnings and Precautions (\n                           5.3\n                        , \n                           5.4), Drug Interactions (\n                           7.3)].\n\n                     who are undergoing acute opioid withdrawal [see Warnings and Precautions (5.3, 5.4), Drug Interactions (7.3)].\n\n                  \n                  If LYBALVI is administered with lithium or valproate, refer to the lithium or valproate Prescribing Information for the contraindications for these products [see Warnings and Precautions (5.18)].",
    "drug": [
        {
            "name": "LYBALVI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7735"
        }
    ]
}